Get the Stockscreener App
0.815
4.06%
0.0318
After Hours:
.83
0.015
+1.84%
Lucid Diagnostics Inc stock is traded at $0.815, with a volume of 178.52K.
It is up +4.06% in the last 24 hours and up +1.82% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.7832
Open:
$0.78
24h Volume:
178.52K
Relative Volume:
1.08
Market Cap:
$40.10M
Revenue:
$2.43M
Net Income/Loss:
$-52.67M
P/E Ratio:
-0.5582
EPS:
-1.46
Net Cash Flow:
$-33.04M
1W Performance:
+4.49%
1M Performance:
+1.82%
6M Performance:
+0.63%
1Y Performance:
-30.34%
1-Day Range:
$0.78
$0.8165
1-Week Range:
$0.7515
$0.82
52-Week Range:
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics' SWOT analysis: esophageal cancer screening stock faces pivotal year - Investing.com UK
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
Lucid Diagnostics to be deconsolidated from PAVmed’s financial statements - Medical Buyer
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance - TipRanks
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Given New $7.25 Price Target at Ascendiant Capital Markets - Defense World
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - StockTitan
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - PR Newswire
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com India
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - Yahoo Finance
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - PR Newswire
Wall Street analysts’ outlook for Lucid Diagnostics Inc (LUCD) - SETE News
Stock Market Recap: Lucid Diagnostics Inc (LUCD) Concludes at 0.84, a -2.10 Surge/Decline - The Dwinnex
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com India
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Analyzing LUCD’s current quarter earnings projections - US Post News
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com Australia
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com UK
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - Yahoo Finance
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - PR Newswire
Lucid Diagnostics (NASDAQ:LUCD) Rating Reiterated by Canaccord Genuity Group - Defense World
Lucid Diagnostics Launches New Corporate Website - Longview News-Journal
PAVmed Inc (PAVM) Q2 2024 Earnings Call Transcript Highlights: R - GuruFocus.com
PAVmed’s EsoGuard revenue for Q2 2024 stands at USD 1.0M - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Lifted to Strong-Buy at Canaccord Genuity Group - Defense World
Cantor Fitzgerald stays bullish on Lucid Diagnostics, keeps $3 target - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Australia
Lucid Diagnostics’ (LUCD) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2024 Earnings Call Transcript - Insider Monkey
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer - Yahoo Finance
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer - PR Newswire
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - Marketscreener.com
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - StockTitan
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - PR Newswire
LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q2 2024 - MSN
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Canada
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com UK
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com Australia
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com Canada
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 - Investing.com
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com UK
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript - Seeking Alpha
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):